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Discovery of “signature” protein proﬁles that distinguish disease states (eg, malignant, benign, and normal) is a key step towards
translating recent advancements in proteomic technologies into clinical utilities. Protein data generated from mass spectrometers
are, however, large in size and have complex features due to complexities in both biological specimens and interfering biochemi-
cal/physical processes of the measurement procedure. Making sense out of such high-dimensional complex data is challenging and
necessitates the use of a systematic data analytic strategy. We propose here a data processing strategy for two major issues in the
analysis of such mass-spectrometry-generated proteomic data: (1) separation of protein “signals” from background “noise” in pro-
tein intensity measurements and (2) calibration of protein mass/charge measurements across samples. We illustrate the two issues
and the utility of the proposed strategy using data from a prostate cancer biomarker discovery project as an example.
INTRODUCTION
With recent advances in mass spectrometry technolo-
gies,itisno wpossibletostudypr oteinpr oﬁlesov erawide
range of molecular weights in small biological specimens
[1]. A key research step in translating these technological
advancements into clinical utilities is the identiﬁcation of
“signature” protein proﬁles that distinguish disease states
(eg,malignant,benign,andnormal)orexperimentalcon-
ditions (eg, treated versus untreated by a drug of inter-
est). For example, a discovery of disease-speciﬁc protein
proﬁles could facilitate early detection of the disease and,
consequently, contribute importantly towards improving
patients’ prognosis and survival.
Protein data generated from mass spectrometers have
complex features due to complexities in both biologi-
cal specimens and interfering biochemical/physical pro-
cesses of the measurement procedure. They are also large
in size, generally in the order of tens of thousands of
measurement points per sample. Making sense out of
such high-dimensional complex data is challenging and
necessitates the use of a systematic data analytic strat-
egy. Speciﬁcally, there are three major issues in the anal-
ysis of mass-spectrometry-generated protein data that
need to be resolved eﬀectively by the systematic strat-
egy: (1) separation of protein “signals” from background
“noise”inproteinintensitymeasurements;(2)calibration
ofproteinmass/chargemeasurementsacrosssamples;and
(3) construction of “signature proﬁles,” as combinations
of multiple mass/charge points, that distinguish disease
states or experimental conditions.
This paper is concerned with the ﬁrst two of the three
issues in the analysis of mass-spectrometry-generated
protein data. We propose a systematic data processing
method for separating signals (protein intensity peaks)
from noise, and for calibrating mass/charge values of pro-
teinsthatmayﬂuctuateslightlyatrandomacrosssamples;
for approaches to the third data analytic problem, several
approaches have been proposed [2, 3, 4, 5, 6].
MATERIALS AND METHODS
In this section, we ﬁrst describe the prostate cancer
biomarker discovery project [4, 5] to illustrate the type of
research settings of interest. The project’s data are used to
explain the signal identiﬁcation and calibration issues. We
then present our proposed data processing method that
addresses these issues.
Theprostatecancerbiomarkerdiscoveryproject
The Department of Microbiology and Molecular Cell
Biology and Virginia Prostate Center of the Eastern
Virginia Medical School (EVMS) have been conduct-
ing a biomarker discovery project on prostate cancer
witha goalof identifying serumprotein biomarkersof the2003:4 (2003) Automated Peak Detection/Calibration of Mass Spectral Data 243
disease.Thisprojectispartofalargeresearchconsortium,
the Early Detection Research Network [7, 8], funded by
the National Cancer Institute. The basis for the protein-
based early detection of cancer is the concept that a trans-
formed cancerous cell and its clonal expansion would re-
sult in up- (or down-) regulation of certain proteins; our
aim is to identify such early molecular signals of prostate
cancer by measuring protein proﬁles in serum.
In this project, serum samples of 386 subjects were re-
trieved from the serum repository of the EVMS Virginia
Prostate Center, approximately equally from four disease
groups: late-stage prostate cancer (N = 98); early-stage
prostate cancer (N = 99); benign prostatic hyperplasia
(BPH)(N = 93);andnormalcontrols(N = 96).Thefour
disease groups were deﬁned as follows: prostate cancer
cases had a positive biopsy that was staged A or B (early-
stage) or C or D (late-stage) and had a prostate speciﬁc
antigen (PSA) concentrations greater than 4ng/ml; BPH
patients had PSA values between 4ng/ml and 10ng/ml,
low PSA velocities, and at least two negative biopsies; and
normal controls were aged 50 or older (ie, the same age
range as cancer and BPH patients), had a PSA level less
than 4ng/ml, and had a normal digital rectal exam.
Each of the retrieved serum samples was assayed at
the EVMS for protein expression by the surface-enhanced
laser desorption/ionization (SELDI) ProteinChip Array
technology [1, 2, 3, 4, 8, 9, 10, 11, 12, 13]o fC i p h e r -
gen Biosystems, Inc, 6611 Dumbarton Circle, Fremont,
CA 94555. The SELDI technology is a time-of-ﬂight mass
spectrometry with a special ProteinChip Array whose
surface captures proteins using chemically or biologi-
cally deﬁned protein-docking sites. Proteins are captured
on the chip surface, puriﬁed by washing the surface,
and crystallized with small molecules called “matrix” or
“energy-absorbing molecules” whose function is to ab-
sorb laser energy and transfer it to proteins. Energized
protein molecules ﬂy away from the surface into a time-
of-ﬂight tube where the time for the molecules to ﬂy
through the tube is a function of the molecular weight
and charge of the protein. A detector at the end of the
tube measures the “intensity” of proteins at each discrete
time of ﬂight and outputs about 48000 data points of
time of ﬂight, intensity pairs. Each discrete time of ﬂight
corresponds uniquely to a ratio of the molecular weight
of a protein to the number of charges introduced by
the ionization. SELDI output, therefore, produces about
48000 data points of mass/charge, intensity pairs. Our
analyses used 16898 data points per sample covering the
mass/charge range of 2000–40000. Figure 1 shows an ex-
ample of SELDI output from the ﬁrst subject in the nor-
mal control group of the prostate cancer biomarker dis-
covery project.
Thetwodataanalyticissues
The ﬁrst data analytic issue is the mathematical def-
inition of “peaks” in protein intensity, that is, the iden-
tiﬁcation of “signals” separated from “noise” in protein
7500 8000 8500 9000 9500 10000
Mass/charge
0
5
10
15
I
n
t
e
n
s
i
t
y
5000 10000 15000 20000
Mass/charge
0
5
10
15
20
I
n
t
e
n
s
i
t
y
Figure 1. An example of SELDI output: the top panel shows the
protein intensity measures (y-axis) in the range of mass/charge
values below 20,000 (x-axis) and the bottom panel zooms into
a subregion covering 7500–10000 mass/charge values.
intensity measurements. Deﬁning protein intensity peaks
mathematically provides two advantages. First, it reduces
the dimensionality of data from tens of thousands of data
pointstoamoremanageablesize(eg,lessthanathousand
data points). Second, perhaps more importantly, it clari-
ﬁes the interpretation of “signature” protein proﬁles, the
end products of the analysis. Speciﬁcally, protein intensity
peaks and their heights at certain mass/charge values in-
dicate thepresenceandthe approximate amount ofcorre-
sponding proteins or peptides in the specimen being an-
alyzed. Without this data reduction step, the “signature”
protein proﬁles that we obtain may not have a clear inter-
pretation: a signature proﬁle can be any pattern of protein
intensity measurements and may not correspond to any
protein intensity peaks.
To illustrate this ﬁrst data analytic issue by a con-
crete example, consider the protein intensity measure-
ments shown in the bottom panel of Figure 1. There are
ﬁve large peaks (signals) that are visually evident in the
plotted range of 7500–10000 mass/charge values. There
are, however, other smaller peaks that are less evident as
to whether or not they represent signals. A good mathe-
matical deﬁnition of peaks would capture, at minimum,
the ﬁve clear peaks, and possibly, less evident ones, but
would also have a high level of speciﬁcity such that the
rest of the data points would not be identiﬁed as peaks.
The second data analytic issue is the calibration of
mass/charge measurements across multiple samples. This
issue can be explained clearly by an example. Figure 2
shows the SELDI output from the ﬁrst four subjects in the
normal control group of the prostate cancer biomarker
discovery project. In the left panel of Figure 2,i ta p p e a r s
that, at least, the ﬁve visually apparent peaks, including
the one marked by “×,” and some less-evident peaks are
alignedwellinthedirectionofthemass/chargeaxisacross
the four samples. When we zoom into the small region
nearthepeakmarkedby“×”(therightpanelofFigure 2),244 Yutaka Yasui et al 2003:4 (2003)
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Figure 2. A set of SELDI output from four subjects: the left panel shows the protein intensity measures in the range of 7500–10000
mass/charge values and the right panel zooms into a small region corresponding to a visually apparent peak. The right panel shows
slight shift in the mass/charge value of an identical peak across the subjects.
however, it becomes apparent that there is slight shift
across the four samples with respect to the mass/charge
values of the peak: there is an approximately 10-dalton
shift between the ﬁrst subject at the top and the fourth
subject at the bottom. The measurement points in this
smallregionareindicatedby“|”atthebottomoftheright
panel of Figure 2: the 10-dalton shift corresponds to a 6-
measurement-point shift in the mass/charge axis.
Although the magnitude of the shift is small, the in-
consistent mass/charge values across samples for an iden-
tical peak present a challenge in data analyses: an identical
peakislabeledbydiﬀerentmass/chargevaluesacrosssam-
ples. Consider, in the right panel of Figure 2, the protein
intensity at the mass/charge value of the peak from the
ﬁrst subject, that is, approximately at 9,294daltons. At
this mass/charge value, the protein intensity for the sec-
ond subject is nearly equal to the intensity value at the
peak. For the third and fourth subjects, however, the pro-
teinintensitiesatthemass/chargevalueareapproximately
half and one quarter, respectively, of the intensities at the
peaks. Thus, even though the magnitude of shifting is
small, assessments of protein intensities by the original
mass/charge values of the SELDI output would be greatly
misleading.
Theproposedsolutionstothetwo
dataanalyticissues
Our proposal for the ﬁrst data analytic issue, the
mathematical deﬁnition of “peaks,” is to deﬁne peaks
by judging, at each mass/charge point, whether or not
the protein intensity at that point is the highest among
its nearest ±N-point neighborhood set, nearest in the
mass/charge-axis direction; if it is the highest, that point
is deﬁned as a peak. We initially considered various val-
ues of N and chose N = 10 by trial and error in order to
be on the inclusive side in classifying peaks; see also our
previous discussion on the selection of N under a slightly
diﬀerent setting [6]. If a more conservative deﬁnition is
preferred, the value of N can be increased.
Our proposal for the second data analytic issue, the
calibration of mass/charge measurements across samples,
is to replace the original mass/charge values of all peaks2003:4 (2003) Automated Peak Detection/Calibration of Mass Spectral Data 245
with a set of calibrated mass/charge values. To describe
our algorithm of the proposed method, we ﬁrst introduce
some terms/concepts that are helpful. We call a range of
potential mass/charge shifting from a mass/charge point
as the “window of potential shift” for that mass/charge
point; and refer to the set of calibrated mass/charge val-
ues as the “new mass/charge set.” Note that the window
of potential shift for a mass/charge point, say P, con-
tains the mass/charge point P itself. Based on quality-
control experiments by the manufacturer of SELDI ma-
chines, it is known that the window of potential shift for
a mass/charge point is approximately ±0.1–0.2% of the
mass/charge value of that point; we used 0.2% in the cur-
rent analysis.
The algorithm is initiated by calculating, at each
mass/charge point, the total number of peaks, in all sam-
ples, that are within the window of potential shift for the
mass/charge point. The mass/charge point that has the
highest total number of peaks (summing over all sam-
ples) within its window of potential shift is entered into
thenewmass/chargesetasacalibratedmass/chargevalue,
and all the mass/charge points that are within the win-
dow of potential shift for this point are removed from
the subsequent steps of the algorithm. Then, the above
procedure is repeated (ie, ﬁnding the point, from the
remaining points, that has the highest total number of
peaks within its window of potential shift, entering it into
the new mass/charge set, and removing the mass/charge
points that are within its window of potential shift from
the subsequent steps of the algorithm) until all peaks are
exhausted from every sample.
The end product of this repeated procedure is the new
mass/charge set. The ﬁnal step of the algorithm is to con-
structacalibrateddatasetthatconsistsofproteinintensity
measures of each sample that correspond to the points in
the new mass/charge set. For each sample, i,a n df o re a c h
point in the new mass/charge set, j, we propose to take
the maximum protein intensity measure of the sample i,
among the protein intensity measures corresponding to
thewindowofpotentialshiftforthepoint j,astheprotein
intensity measure Yij at the calibrated mass/charge point
j.Theﬁnalcalibrateddatasetis {Yij}whoseelementsrep-
resent protein intensity measures indexed by the sample
number i and the calibrated mass/charge value j.
Anapplicationofthecalibrateddataset
tobiomarkerdiscovery
To illustrate the utility of the calibrated dataset pro-
duced by the proposed method, we applied it to a con-
struction of “signature proﬁles” of disease states in the
prostate cancer biomarker discovery project. The 386
serumsamplesoftheprojectwereseparatedbyastratiﬁed
random sampling into “test data” (a total of 60, 15 sam-
ples from each of the four disease states: late- and early-
stage prostate cancer; BPH; and normal) and “training
data”(theremaining326samples).Thetrainingdatawere
used to construct a calibrated dataset, from which signa-
ture proﬁles were derived for classifying the three disease
states of interest (ie, cancer, BPH, and normal). To test
the performance of the derived signature proﬁles inde-
pendently from the training data, the test data was used
as follows. First, a calibrated test dataset {Zij} was con-
structed by setting, for each test sample i and each cal-
ibrated mass/charge value j that appears in the derived
signature proﬁles, the maximum protein intensity mea-
sure Yij within the window of potential shift for j as Zij.
Second, the signature proﬁles derived from the training
data were applied to the calibrated test dataset to classify
each test sample into the three disease states. Finally, the
classiﬁcation errors in the test data were assessed compar-
ing the classiﬁed disease states with the true disease states.
The stratiﬁed sampling that created the training and test
data was conducted by a statistician (DM) who received
the data from the EVMS laboratory, and the disease states
of the test samples were blinded to all data analysts.
In the analysis of the training data, the protein-
intensity measure, Yij, for sample i at calibrated mass/
charge value j, was transformed because of its heavily
skewed distribution. The transformed protein intensity
measure, Tij,i sg i v e nb y
Tij = ln

Yij −cj +1

−si, (1)
where cj is the minimum protein intensity measure at the
calibrated mass/charge value j among all training sam-
ples, which makes the logarithmic transformation possi-
ble, and si is the mean value of ln(Yij−cj +1) of the sam-
ple i across all calibrated mass/charge values. The subtrac-
tionofsi aimstoremovethesample-speciﬁcmeanprotein
intensity since a number of sample-speciﬁc factors could
modify the amounts and measurementsof proteins across
samples. The same transformation was also employed in
the analysis of the test data {Zij}.
The signature proﬁles (classiﬁers of the disease states)
were constructed using two logistic regression models:
one for classifying cancer/BPH versus normal and the
other classifying cancer versus BPH. The two logistic re-
gression analyses used the respective disease states as out-
come variables and transformed protein intensity mea-
sures {Tij} as potential covariates, selecting only those
with signiﬁcant associations with the disease states (at
P = .0001 and P = .0005 levels, resp.) by a forward vari-
able selection method.
RESULTS AND DISCUSSION
Results
Figure 3 shows the peaks identiﬁed by the proposed
peak identiﬁcation method. Our simple mathematical
deﬁnition of peaks captured both visually apparent and
some less-evident peaks. The number of peaks identiﬁed
per sample was similar across the four disease states: the
median (range) of 469 (361–571), 463 (389–596), 467
(367–555), and 444 (390–559) for the groups of late-stage246 Yutaka Yasui et al 2003:4 (2003)
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Figure 3. Peaks identiﬁed by the proposed peak identiﬁca-
tion method, marked by “×,” in the range of 7,500–10,000
mass/charge values, corresponding to the bottom panel of
Figure 1.Thetoppanelshowstheoriginalproteinintensitymea-
sures in the y-axis, while the bottom panel shows transformed
protein intensity measures in the y-axis for ease in examining
the peaks.
cancer, early-stage cancer, BPH, and normal control, re-
spectively.
Figure 4 shows calibration of one of the visually
apparent peaks in Figure 2 by the proposed method.
The ﬁrst four samples of the normal control group
had peaks that were slightly shifted in the direction of
the mass/charge axis around 9300 mass/charge value.
The calibrated mass/charge value corresponding to these
peaks was 9306.2 and, as shown in Figure 4, the four pre-
viously shifted peaks are now lined up at this calibrated
mass/charge value with the original protein-intensity
measures being used as {Yij}. The intensity values at
9,306.2 mass/charge value changed from 7.87, 9.90, 6.40,
15.18 before the calibration to 8.61, 10.73, 7.04, 15.59 af-
ter the calibration in the four samples.
After the calibration, the number of mass/charge val-
ues in the new mass/charge set was 957. This represents
a considerable reduction of data from 16898 points per
sample to 957 (5.7% of 16898) in the range of 2000–
40000 mass/charge values. Figure 5 shows the number of
mass/charge values in the new mass/charge set accord-
ing to their values. The number in the new mass/charge
set was highest in the smallest values of mass/charge and
monotonically decreased for larger mass/charge values.
The calibrated dataset was then used in the logistic re-
gression analysis to construct signature proﬁles of three
disease states (cancer, BPH, and normal). With the 957
log-transformed protein intensity measures as potential
covariates, the forward selection method identiﬁed four
calibrated mass/charge values that were signiﬁcantly asso-
ciatedwiththeclassiﬁcationofcancer/BPHversusnormal
at P = .0001 level. Similarly, seven calibrated mass/charge
valueswereselectedintothemodelfortheclassiﬁcationof
Table 1. Test data classiﬁcation results of the logistic-model-
based classiﬁers constructed using the calibrated training
dataset.
Predicted by models True disease state
Cancer BPH Normal
Cancer 27 2 0
BPH 11 3 0
Normal 20 1 5
cancer versus BPH at P = .0005 level. Note that the four
andsevenselectedmass/chargevalueswerethoseatwhich
some samples showed peaks in protein intensity. Based on
ﬁtted probabilities from the two logistic regression mod-
els, the 60 test data samples were classiﬁed into the three
diseasestates.Ofthe60testdatasamples,55(91.6%)were
correctly classiﬁed, suggesting the high utility of the cali-
brated dataset, even with this simple classiﬁer construc-
tion method using the standard forward selection logistic
regression analysis.
Discussion
Previously in this project, the peak identiﬁcation and
mass/charge value calibration were performed manually,
taking a signiﬁcant amount of human eﬀort and time [4].
The proposed data processing method was motivated to
automate the human processing of the SELDI output by
the use of computers. It mimics the steps of the previous
manual processing and aims to eliminate potential hu-
man errors in dealing with the high-dimensional complex
data. The excellent performance in classiﬁcation shown in
Table 1 suggests the high utility of the data produced by
the proposed data processing method.
There are important advantages in separating the data
processing stage, as proposed here, from the subsequent
signature proﬁle construction stage. First, the proposed
method can be applied with complete blinding to the dis-
ease states of samples, ensuring an unbiased data process-
ingacrosssamples.Neitherthepeakidentiﬁcationnorthe
mass/charge-axis calibration of our proposed method re-
quires knowledge of the disease state of each sample. Sec-
ond, by separating the two stages that have distinct data
analytic issues, we are able to consider various targeted
approaches for resolving the stage-speciﬁc data analytic
issues.
A limitation in our proposed method for the cali-
bration of mass/charge values is that the calibration pro-
cedure depends on the dataset being analyzed, that is,
the sets of calibrated mass/charge values from multiple
datasets may not agree. This is perhaps not a critical is-
sue at the biomarker discovery stage of research, such as
the prostate cancer biomarker discovery project discussed
here, since the data analysis for the biomarker discovery
would use a single dataset. If the data are measured us-
ing multiple SELDI machines, either at one laboratory or
at multiple laboratories, the dataset-dependent nature of2003:4 (2003) Automated Peak Detection/Calibration of Mass Spectral Data 247
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Figure 4. Calibration of a visually apparent peak in Figure 2 by the proposed method.
0 10000 20000 30000 40000
Mass/charge
0
50
100
150
200
250
N
u
m
b
e
r
i
n
t
h
e
n
e
w
m
a
s
s
/
c
h
a
r
g
e
s
e
t
Figure 5. Number of mass/charge points in the new calibrated
mass/charge set according to their mass/charge values.
the proposed method needs to be considered carefully.
If datasets generated by multiple SELDI machines are
combined, additional sources of variations are introduced
(eg, between machine and laboratory variations). The
“window of potential shift” of a mass/charge value in
the combined dataset would, therefore, be expected to be
largerthanthe ±0.1–0.2%consideredhere,thatwasbased
on the quality-control data of the SELDI manufacturer. It
is necessaryto eitheruse a widerwindow of potential shift
or add an extra step in the method to minimize the ad-
ditional variation when combining datasets generated by
multiple SELDI machines.
A potential improvement of the proposed method is
to make the mathematical deﬁnition of peaks such that
it copies closely the thought process of experienced mass
spectrometry experts in identifying peaks. Although our
simple deﬁnition appears reasonable and functional, it
would certainly enhance the method if a peak identiﬁ-
cation procedure similar to that of experts could be im-
plemented. For example, a learning algorithm can be ap-
plied to a large dataset that is read and peak-identiﬁed by
experts so that details of experts’ procedures may be rec-
ognized for possible implementation in the mathematical
deﬁnition.
In summary, we proposed an automatic data pro-
cessing procedure for the peak identiﬁcation and mass/
charge-axis calibration problems for mass-spectrometer-248 Yutaka Yasui et al 2003:4 (2003)
generated protein measures. Our procedure is easy to im-
plement and appears to work eﬀectively as evidenced in
the excellent classiﬁcation performance by the resulting
calibrated dataset. There are points to improve in the pro-
posed method and additional issues to resolve when it is
applied to multiple datasets generated by more than one
SELDI machine. We hope to resolve these issues in our
future research.
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